Hims & Hers (HIMS) Soars 10.3% on Analyst Upgrades, New Deal

Core Viewpoint - Hims & Hers Health Inc. has seen a significant stock price increase due to renewed investor interest following analyst upgrades and a renewed partnership with Novo Nordisk [1]. Group 1: Stock Performance - Hims & Hers stock rose by 10.27% to close at $25.88, marking the third consecutive day of gains [1]. - The stock is among the top 10 movers in the market today [1]. Group 2: Analyst Upgrades - Deutsche Bank, Citigroup, and Bank of America have all raised their price targets for Hims & Hers to $28, $24, and $23, respectively, from previous targets of $25, $13.25, and $12.50 [2]. - Citigroup and Bank of America upgraded their ratings to "neutral" from "sell" and "underperform," respectively, while Deutsche Bank maintained a "neutral" stance [4]. Group 3: Partnership with Novo Nordisk - Hims & Hers renewed its partnership with Novo Nordisk, agreeing to discontinue the sale and marketing of compounded versions of Novo's drugs, Wegovy and Ozempic [5]. - The company will only provide access to its own GLP-1 products when FDA-approved versions do not meet customer needs and if deemed clinically necessary by a provider [5].